Sagimet Biosciences Inc.

Analysis for Ticker: SGMT

Sagimet Biosciences Inc is a clinical-stage pharmaceutical company that claims to be developing specialized chemicals to treat liver disease and severe acne. In reality, the company is a sixteen-person office that owns no manufacturing plants, operates no laboratories, and has never generated one dollar in commercial sales. Since its inception, it has managed to lose 336,8$ million. This is a mathematical disaster because the company survives solely by printing new pieces of ownership and selling them to investors to pay for its massive overhead. It is a system where the company pays for its existence by slowly selling off its own future, piece by piece, until nothing remains. The survival mechanism began in 01/2024, when the company pulled 104,7$ million from the market by selling nine million shares for 12,50$ each. By 18/07/2025, the extraction moved inside the office as the executive chairman, George Kemble, was handed 37.688 shares for zero dollars. To keep the cash flowing, management created a legal setup in 08/2025 that allows them to dump up to 75$ million in new shares onto the public at any time. Kemble then signed a plan to sell his free shares before the market could react to the coming dilution.